ArticlePharmaceuticals (Basel, Switzerland)2026
Population Pharmacokinetic Analysis and Modelling of Serum Uric Acid Dynamics in Patients Treated with Favipiravir.
Tomona Yamada, Hitoshi Kawasuji, Chika Ogami, Chihiro Hasegawa, Makito Kaneda, Daichi Yamaguchi, Satofumi Iida, Takahiko Aoyama, Yoshihiro Yamamoto, Yasuhiro Tsuji
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Tomona YamadaLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.ORCID 0009-0002-1370-4202 Hitoshi KawasujiDepartment of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0002-5536-101X Chika OgamiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.
Chihiro HasegawaLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.
Makito KanedaDepartment of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Daichi YamaguchiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.ORCID 0009-0007-9455-5638 Satofumi IidaLaboratory of Clinical Pharmacology, Yokohama University of Pharmacy, 601 Matano-cho, Totsuka-ku, Kanagawa 245-0066, Japan.
Takahiko AoyamaLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.ORCID 0000-0001-6111-8537 Yoshihiro YamamotoDepartment of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0003-2088-8724 Yasuhiro TsujiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan.ORCID 0000-0002-7967-2947 Funding
Nihon University x
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
favipiravirhydroxylated metabolitehyperuricemiapharmacodynamicspopulation pharmacokineticsuric acid
Identifiers
PMID42515693
PMCPMC13416278
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390